Search Results
Your search for 3 matches 15507 pages
Showing 15201 - 15250Oral Ibandronic Acid Is Not Noninferior to IV Zoledronic Acid in Preventing Skeletal-Related Events in Patients With Breast Cancer
In a phase III noninferiority trial (ZICE) reported in The Lancet Oncology, Barrett-Lee et al compared oral ibandronic acid vs intravenous zoledronic acid in treatment of bone metastases from breast cancer. The study showed that ibandronic acid was not noninferior to zoledronic acid in preventing...
Low-Dose CT Screening May Result in Overdiagnosis of Lung Cancer
In a study reported in JAMA Internal Medicine, Patz et al of the NLST Overdiagnosis Manuscript Writing Team estimated the magnitude of overdiagnosis using low-dose computed tomography (CT) screening for lung cancer in the National Lung Screening Trial (NLST). They estimated that more than 18% of...
Julie M. Vose, MD, MBA, FASCO, Elected ASCO President for 2015-2016 Term
Julie M. Vose, MD, MBA, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2015. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2014. Additionally, four new members were elected to the...
Anti–PD-1 Antibody Pidilizumab Plus Rituximab Shows High Activity in Relapsed Follicular Lymphoma
Antitumor immune responses may be inhibited by immune checkpoints in the tumor microenvironment including effects of PD-1 (programmed cell death 1), a co-inhibitory receptor on tumor T cells that impairs T-cell function. In a phase II study reported in The Lancet Oncology, Westin et al assessed the ...
No Survival Benefit for Tecemotide After Chemoradiotherapy in Stage III NSCLC
In the phase III START trial reported in The Lancet Oncology, Butts et al assessed whether maintenance treatment with the MUC1 antigen–specific immunotherapy tecemotide could prolong overall survival in patients with unresectable stage III non–small cell lung cancer (NSCLC) who had...
EUROCARE-5: Trends in Survival for Childhood Cancers
As reported in The Lancet Oncology by Gatta et al, the population-based EUROCARE-5 study has shown improved survival for all childhood cancers combined in Europe between 1999–2001 and 2005–2007 and persistence of regional survival disparities. Study Details The study involved analysis ...
No Overall Survival Benefit With Addition of Sunitinib to Prednisone in Metastatic Castration-Resistant Prostate Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Michaelson et al assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to prednisone in patients with progressive metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. No...
Low hENT1 Is Associated With Poorer Survival in Patients With Pancreatic Cancer Receiving Adjuvant Gemcitabine
In a study reported in the Journal of the National Cancer Institute, Greenhalf et al analyzed the association between human equilibrative nucleoside transporter 1 (hENT1) levels and survival in patients with pancreas cancer receiving adjuvant gemcitabine or fluorouracil (5-FU)/leucovorin after ...
Suboptimal Adverse Event Reporting in Cancer Clinical Trial Publications
In a study reported in the Journal of Clinical Oncology, Sivendran et al assessed the degree to which publication of phase III trials in oncology conformed with CONSORT (Consolidated Standards of Reporting Trials) recommendations for reporting adverse events. They found that adverse event...
No Benefit of Calcium/Magnesium in Preventing Oxaliplatin-Induced Sensory Neurotoxicity in Patients With Colon Cancer
In a phase III N08CB/Alliance trial reported in the Journal of Clinical Oncology, Loprinzi et al assessed whether calcium and magnesium treatment reduced oxaliplatin-related neurotoxicity in patients with colon cancer receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin). They found ...
CALGB 40603 Trial Supports Adding Carboplatin to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
The addition of carboplatin to a neoadjuvant regimen significantly increased the rate of pathologic complete response in patients with triple-negative breast cancer. The results from the CALGB/Alliance 40603 study were reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S5-01)....
Survival Benefit With High-Dose Cytarabine Induction in AML Patients Aged < 46 Years
In a European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) phase III trial (AML-12) reported in Journal of Clinical Oncology, Willemze et al compared induction regimens containing high-dose or standard-dose...
Adjuvant Paclitaxel/Trastuzumab Tolerable, Benefits Women With Stage I HER2-Positive, Node-Negative Breast Cancer
There may be a benefit for treating small HER2-positive tumors and this can be done with little toxicity, according to a multicenter study presented at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-04). Previous studies of chemotherapy plus anti-HER2 treatment for node-negative...
Nonsignificant Reduction in Breast Cancer Risk Seen With Low-Dose Tamoxifen in Postmenopausal Hormone Replacement Therapy Users
In postmenopausal women receiving hormone replacement therapy, low-dose tamoxifen did not significantly reduce the risk of breast cancer but did increase climacteric symptoms, according to the phase III study results presented by DeCensi et al in the Annals of Oncology. However, beneficial trends...
Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rate in Initial Therapy for Follicular Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Illidge et al evaluated radioimmunotherapy with fractionated 90Y-ibritumomab tiuxetan (Zevalin) as initial treatment in patients with mostly advanced follicular lymphoma. The treatment was well tolerated, with manageable...
Less Is More: Postoperative Radiation May Be Avoided in Older Women With Estrogen Receptor–Rich Tumors
Among older women with hormone receptor–positive breast cancer, it is reasonable to omit whole-breast radiation therapy after breast-conserving surgery and neoadjuvant hormone therapy if the patient’s tumors have high levels of estrogen receptor expression, but radiation should remain...
NeoALTTO Trial Links Pathologic Complete Response to Clinical Outcomes
Final results of the phase III NeoALTTO trial have confirmed the value of pathologic complete response to dual HER2 blockade in the neoadjuvant setting. The achievement of pathologic complete response was associated with significantly improved event-free survival and overall survival in some women...
No Difference in PFS for Temsirolimus vs Sorafenib as Second-Line Therapy After Sunitinib in Metastatic RCC
In the phase III INTORSECT trial reported in the Journal of Clinical Oncology, Hutson et al compared temsirolimus (Torisel) vs sorafenib (Nexavar) as second-line treatment in patients with metastatic renal cell carcinoma after progression on sunitinib (Sutent). There was no significant difference...
No Difference Between Temsirolimus/Bevacizumab vs Interferon Alfa/Bevacizumab in First-Line Therapy for Metastatic Renal Cell Carcinoma
In the phase III INTORACT trial reported in the Journal of Clinical Oncology, Rini et al compared temsirolimus (Torisel)/bevacizumab (Avastin) vs interferon alfa/bevacizumab in first-line treatment of metastatic renal cell carcinoma. There were no significant differences between the two regimens in ...
Ibrutinib/Rituximab Combination Leads to High Response Rate Among Patients With CLL
Nearly all of the patients with high-risk chronic lymphocytic leukemia (CLL) in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib (Imbruvica) and the antibody rituximab (Rituxan), researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting ...
Biologic Doublet a Potential Front-Line Treatment in Mantle Cell Lymphoma
A high proportion of mantle cell lymphoma patients may achieve an objective and durable response to treatment with an initial chemotherapy-free regimen, according to Jia Ruan, MD, PhD, of Weill Cornell Medical College, New York, who presented the results of a multicenter phase II study at the 55th...
Idelalisib Achieves High Response Rates in 'Double-Refractory' Indolent NHL
In patients with indolent B-cell non-Hodgkin lymphoma (NHL) refractory to both rituximab (Rituxan) and an alkylating agent, monotherapy with the selective oral PI3K-delta inhibitor idelalisib produced a high response rate, with responses persisting for 1 year in the average patient, according to...
Gemtuzumab Ozogamicin Reduces Relapse, Improves Event-Free Survival in Pediatric AML
The monoclonal antibody gemtuzumab ozogamicin (Mylotarg) improved event-free survival and reduced the risk of relapse in children with acute myeloid leukemia (AML) in a study from the Children’s Oncology Group, presented at the 55th American Society of Hematology (ASH) Annual Meeting and...
Successful Chimeric Antigen Receptor–Expressing T-Cell Treatment Reported in Advanced Lymphomas
Development of autologous genetically engineered anti-CD19 chimeric antigen receptor (CAR)-expressing T cells holds promise in the treatment of hematologic malignancies. CAR T cells are being studied in adult and pediatric acute lymphocytic leukemias and in chronic lymphocytic leukemia, and...
Grade 3 Endometrioid Carcinoma With PIK3CA Mutation Linked to Unfavorable Outcome
The presence of PIK3CA missense mutation appears to be associated with shorter disease-specific survival in grade 3 endometrioid but not serous endometrial carcinoma, according to a study in Gynecologic Oncology. Although McIntyre et al found this type of mutation across all histologic types of...
PPM1D Mutations in Circulating White Blood Cells Associated With Risk of Ovarian Cancer, Increased Mortality, and Risk of Breast Cancer
In a brief communication published in the Journal of the National Cancer Institute, Akbari et al reported finding a higher frequency of PPM1D mutations in circulating white blood cells from women with ovarian cancer vs controls, higher mortality associated with the mutation in women with ovarian...
Nonsignificant Survival Benefit With Postoperative Radiation Therapy for Head and Neck Cancer at Academic Center vs Other Institutions
In a study reported in JAMA Otolaryngology Head & Neck Surgery, George et al evaluated radiation treatment characteristics and outcomes among head and neck squamous cell carcinoma patients receiving adjuvant external-beam radiation therapy at an academic center vs other institutions....
Nurse Navigators Improve Patient-Reported Quality of Care in Early Cancer Care
In a study reported in the Journal of Clinical Oncology, Wagner et al assessed whether a nurse navigator intervention improved quality of life or patient experience with care in patients who recently received a diagnosis of breast, colorectal, or lung cancer. Although no differences in...
Three-Drug Regimen Produces High Response Rate in Relapsed/Refractory Multiple Myeloma
A phase II trial to evaluate the combination of bendamustine (Treanda) with bortezomib (Velcade) and dexamethasone in patients with relapsed/refractory multiple myeloma “showed a remarkable response rate of 60.9%, and, when minor responses were included in 75.9% of patients,”...
Low-Fat Diet and Fish Oil Supplementation Reduces Cell-Cycle Progression in Prostate Cancer
In a post hoc analysis reported in the journal Cancer Prevention Research, Galet et al analyzed the effects of diet on men with prostate cancer. They found that men who were on a low-fat diet and fish oil supplementation had lower cell-cycle progression scores, which are associated with less...
Thyroid Ultrasound Strategy Identifies Low-Risk Patients Who Can Defer Biopsy
In a study reported in JAMA Internal Medicine, Smith-Bindman et al evaluated the ability of ultrasound imaging characteristics to determine risk of thyroid cancer associated with thyroid nodules. They found that a strategy of using two abnormal nodule characteristics as an indication for biopsy...
ASCO Endorses Cancer Care Ontario Guideline for Follow-up in Colorectal Cancer Survivors
ASCO has policy and procedures for endorsing clinical practice guidelines developed by other professional organizations. As reported in the Journal of Clinical Oncology by Meyerhardt et al of the ASCO Clinical Practice Guidelines Committee, ASCO has endorsed the Cancer Care Ontario (CCO)...
Interim Phase I/II Clinical Trial Data for VAL-083 Show Clinical Activity in Refractory Glioblastoma
Interim phase I/II clinical trial data for VAL-083—a bifunctional DNA alkylator that crosses the blood-brain barrier with preferential accumulation in brain tumor tissue—in patients with recurrent glioblastoma multiforme were presented by Shih et al at the 4th Quadrennial Meeting of the ...
Internet-Based Intervention Improves Cancer-Related Sexual Dysfunction in Women
An Internet-based intervention may significantly improve both sexual function and satisfaction in women with sexual dysfunction years after treatment for breast or gynecologic cancer, according to a randomized trial reported in the November issue of the Journal of the National Comprehensive Cancer...
Brentuximab Vedotin Plus ABVD or AVD Is Highly Active in Newly Diagnosed Hodgkin Lymphoma
Brentuximab vedotin (Adcetris) is active in patients with relapsed/refractory Hodgkin’s lymphoma. In a phase I study reported in The Lancet Oncology, Anas Younes, MD, of Memorial Sloan-Kettering Cancer Center (formerly of The University of Texas MD Anderson Cancer Center), and colleagues...
Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...
Targeted Intraoperative Radiotherapy Concurrent With Lumpectomy Noninferior to External-Beam Radiotherapy in Preventing Local Breast Cancer Recurrence
In a randomized noninferiority trial (TARGIT-A) reported in The Lancet, Jayant S. Vaidya, PhD, and Michael Baum, MD, of University College London, and colleagues compared risk-adapted radiotherapy using single-dose targeted intraoperative radiotherapy vs fractionated external-beam radiotherapy in...
No Advantage of Concurrent vs Sequential Trastuzumab/Anthracycline Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
In the phase III Z1041 trial reported in The Lancet Oncology, Aman U. Buzdar, MD, of The University of Texas MD Anderson Cancer Center, and colleagues compared neoadjuvant therapy with FEC-75 (fluorouracil [5-FU], epirubicin, and cyclophosphamide) followed by paclitaxel plus trastuzumab (Herceptin) ...
Additional Interim Data for Lambrolizumab Show Survival Benefit for Patients With Advanced Melanoma
Additional data for the investigational anti–PD-1 immunotherapy lambrolizumab (MK-3475) were presented yesterday at the 10th International Congress of the Society for Melanoma Research in Philadelphia. In patients with advanced melanoma, lambrolizumab demonstrated an estimated 1-year overall...
Most Patients Experience Nocturnal Care Disturbances Following Hematopoietic Stem Cell Transplantation
In a study reported in the Clinical Journal of Oncology Nursing, Eileen Danaher Hacker, PhD, APN, AOCN, of the University of Illinois College of Nursing, and colleagues attempted to identify and quantify nocturnal care disruptions in patients undergoing hematopoietic stem cell transplantation. They ...
International Ki67 Reproducibility Study Shows High Intralaboratory but Only Moderate Interlaboratory Reproducibility
In a study reported in Journal of the National Cancer Institute, Mei-Yin C. Polley, PhD, of the National Cancer Institute, and colleagues assessed intralaboratory and interlaboratory variability in Ki67 scoring. They found high intralaboratory reproducibility but only moderate interlaboratory...
No Benefit From Adding Cetuximab to Pemetrexed in Recurrent/Progressive NSCLC After Platinum-Based Therapy
In a phase III trial reported in The Lancet Oncology, Edward S. Kim, MD, of Levine Cancer Institute, Carolinas HealthCare System, and colleagues investigated whether the addition of cetuximab (Erbitux) to pemetrexed (Alimta) improved progression-free survival in patients with recurrent or...
Surgical Management of Male Breast Cancer Differs Dramatically From That of Female Breast Cancer
In a study reported in the International Journal of Radiation Oncology Biology Physics, Emma C. Fields, MD, of the University of Colorado School of Medicine, and colleagues analyzed the stage-specific management of male breast cancer with surgery and radiation therapy and related them to outcomes...
Prognostic Score Predicts Overall Survival in Older Patients With Hodgkin Lymphoma by Second-Line Treatment Strategy
In a study reported in the Journal of Clinical Oncology, Boris Böll, MD, of University Hospital Cologne, and colleagues analyzed second-line treatment and survival in older patients with relapsed/refractory Hodgkin lymphoma in German Hodgkin Study Group first-line studies. Use of a...
Dasatinib Plus Docetaxel Does Not Improve Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Data suggest that Src kinase-mediated interactions between prostate cancer cells and osteoclasts might promote bone metastasis and that the Src kinase inhibitor dasatinib (Sprycel) might exhibit synergy with docetaxel in prostate cancer. In a phase III trial (READY) reported in The Lancet Oncology, ...
Study Explains Cyclophosphamide’s Role in Preventing Graft-vs-Host Disease
Results of a Johns Hopkins study may explain why cyclophosphamide prevents graft-vs-host disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of graft-vs-host...
Assay-Sensitive Treatment Improves Outcomes in Recurrent Ovarian Cancer
The use of assay-sensitive treatment significantly improved both progression-free survival and overall survival compared with nonsensitive treatment in women with recurrent ovarian cancer, according to the results of a prospective clinical trial reported in Gynecologic Oncology. Thomas Rutherford,...
Persistent Significant Neurocognitive Impairment in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
In a study reported in the Journal of Clinical Oncology, Kevin R. Krill, PhD, and colleagues from St. Jude Children’s Research Hospital assessed neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia (ALL). They found pervasive significant impairment across...
Increased Prevalence but Reduced Mortality of Venous Thromboembolism After Major Cancer Surgery
In a study reported in JAMA Surgery, Vincent Q. Trinh, BSc, of the University of Montreal Health Centre, and colleagues assessed trends in incidence and mortality of venous thromboembolism after major cancer surgery in the United States between 1999 and 2009. They found that venous thromboembolism...
Basaloid Squamous Cell Carcinoma Not Predictive of Worse Outcome vs Squamous Cell Carcinoma in Head and Neck Cancer
In a study reported in JAMA Otolaryngology-Head & Neck Surgery, Okechukwu R. Linton, MD, MBA, of Indiana University School of Medicine, and colleagues assessed the prognostic significance of head and neck basaloid squamous cell carcinoma, which is considered a more aggressive form of squamous...
